Search TMDX
TransMedics Group, Inc.
Nasdaq · CIK 1756262
Last close79.79
Daily change+1.15 (1.47%)
10 Years gain+256.86%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TMDX · STANDARD
SIC 3845 · Electromedical & Electrotherapeutic Apparatus · Fiscal year end 1231
Fundamental
82.2Momentum
62.1Acceleration
62.1Confidence
84.0Annual Revenue9
Quarterly Revenue30
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality17.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 2.4229 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM43.5%OK
Revenue CAGR 3Y86.42%OK
Gross Margin59.47%OK
Operating Margin14.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC55.86%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.99%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $605.49M | $362.81M | $108.58M | $192.84M | $133.59M | 59.92% | 17.93% | 22.06% | n/a | 40.54M |
| 2025 FY Dec 31, 2024 | $441.54M | $262.08M | $37.50M | $48.80M | -$80.94M | 59.36% | 8.49% | -18.33% | n/a | 35.22M |
| 2025 FY Dec 31, 2023 | $241.62M | $154.09M | -$28.73M | -$13.03M | -$164.88M | 63.77% | -11.89% | -68.24% | n/a | 32.52M |
| 2024 FY Dec 31, 2022 | $93.46M | $65.27M | -$31.44M | -$45.82M | -$57.72M | 69.84% | -33.64% | -61.76% | -89.52% | 29.56M |
| 2023 FY Dec 31, 2021 | n/a | $21.16M | -$39.43M | -$28.86M | -$32.38M | n/a | n/a | n/a | n/a | 27.62M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $665.07M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-332843, 0001193125-25-256377 |
| Revenue Growth TTM | 43.5% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-332843, 0001193125-25-256377 |
| Revenue CAGR 3Y | 86.42% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-067032 |
| Revenue CAGR 5Y | 88.21% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-067032 |
| Gross Profit CAGR 3Y | 77.14% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-067032 |
| Operating Income Growth | 72.13% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-332843, 0001193125-25-256377 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 59.47% | Gross Profit / Revenue | OK | 0001193125-26-332843, 0001193125-25-256377 |
| Operating Margin | 14.57% | Operating Income / Revenue | OK | 0001193125-26-332843, 0001193125-25-256377 |
| ROIC | 55.86% | NOPAT / Average Invested Capital | OK | 0001193125-26-332843, 0001193125-25-256377 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332843 |
| Current Ratio | 6.63x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 24.56x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-332843 |
| Revenue per Diluted Share | $16.34 | Revenue / Diluted Shares | OK | 0001193125-26-332843, 0001193125-25-256377 |